Flaxseed Extract (SDG) for Women’s Health Supplements: What the Clinical Research Shows
As a flaxseed extract SDG supplier, Nutrayours provides one of the most clinically supported phytoestrogen ingredients for nutraceutical formulators and women’s health supplement brands.. Unlike many botanical ingredients that rely primarily on traditional use or in vitro data, flaxseed lignans have been evaluated in multiple randomized controlled trials in human populations — making them a strong foundation for evidence-based product claims.
This article reviews the current clinical research on flaxseed extract SDG, with a focus on applications in women’s health formulations, and provides practical sourcing guidance for manufacturers.
What Is Flaxseed Extract (SDG)?
Flaxseed (Linum usitatissimum) is the richest dietary source of plant lignans, containing predominantly secoisolariciresinol diglucoside (SDG). SDG is a glycosylated lignan — meaning it is bound to glucose molecules in the plant — which is released during digestion and then further metabolized by intestinal bacteria into two biologically active mammalian lignans: enterodiol (END) and enterolactone (ENL).
This gut microbiome-dependent conversion is central to flaxseed extract’s mechanism of action. Enterodiol and enterolactone are structurally similar to endogenous estrogens and can interact with estrogen receptors, exerting weak estrogenic or anti-estrogenic effects depending on the hormonal environment. This makes SDG particularly relevant for women’s health applications where hormonal modulation is desired without the risks associated with synthetic hormone therapy.
For supplement manufacturers, standardized flaxseed extract (SDG 20%–50%) provides a consistent, measurable active content that whole flaxseed cannot — making it the preferred ingredient for capsule, tablet, and functional food formulations.
Clinical Evidence: Menopause and Perimenopause
The most robust clinical data for flaxseed extract SDG relates to menopausal and perimenopausal symptom relief — an application with growing commercial relevance as the global women’s health supplement market expands.
A randomized controlled trial published in Cureus (2024) evaluated flaxseed supplementation in perimenopausal women using a single-blind, placebo-controlled design. Following three months of supplementation, the intervention group showed substantially lower menopausal symptoms compared to the placebo group (p<0.001). Enterodiol and enterolactone levels were also considerably higher in the supplemented group (p<0.001), confirming that SDG was being effectively metabolized to its active forms.
A separate six-month randomized trial involving 90 menopausal women compared flaxseed extract (1g/day containing 100mg SDG) against flaxseed meal (90g/day containing 270mg SDG) and a collagen placebo. Menopausal symptoms were assessed using the Kupperman Index — a validated clinical tool measuring hot flashes, insomnia, nervousness, joint pain, and other symptoms. Both the flaxseed extract and flaxseed meal groups showed significant reductions in the Kupperman Index compared to placebo. Importantly, no adverse estrogenic effects on endometrial thickness or vaginal cytology were observed in either group — a critical safety consideration for formulators targeting postmenopausal women.
A 2024 review published in Integrative Cancer Therapies examined multiple botanical medicines for menopausal vasomotor symptoms and concluded that flaxseed lignans demonstrated both safety and efficacy for hot flashes and night sweats, with the standardized extract format (100mg SDG/day) showing consistent results across studies.
Key formulation insight: The clinical research consistently uses SDG doses of 100–300mg per day. For capsule formulations using flaxseed extract standardized to 20% SDG, this translates to 500mg–1,500mg of extract per daily serving — a practical and cost-effective inclusion rate.
Clinical Evidence: Cardiovascular Health
Beyond menopausal applications, SDG has demonstrated cardiovascular benefits relevant to women’s health and healthy aging formulations.
A clinical trial registered at Iowa State University (NCT01314586) evaluated the effect of 150mg or 300mg/day of SDG-containing flaxseed extract on serum cholesterol in hypercholesterolemic adults. The hypothesis, supported by prior animal and human data, was that flaxseed lignans lower total and LDL cholesterol while also reducing blood pressure and fasting glucose.
A comprehensive review published in PubMed identified that SDG metabolites may protect against cardiovascular disease and metabolic syndrome by reducing lipid and glucose concentrations, lowering blood pressure, and decreasing oxidative stress and inflammation. The review noted that a dose of at least 500mg SDG per day for approximately 8 weeks is needed to observe positive effects on cardiovascular risk factors in human patients.
For formulators, this positions flaxseed extract SDG as a viable ingredient in cardiovascular support formulations targeting postmenopausal women — a demographic with elevated cardiovascular risk due to declining estrogen levels.
Clinical Evidence: Antioxidant and Anti-Inflammatory Activity
SDG and its metabolites demonstrate significant antioxidant activity through multiple mechanisms. A broad review of SDG research published in PMC identified antioxidant, anti-inflammatory, antimutagenic, and antimicrobial properties, with particular evidence for SDG’s role in reducing oxidative stress markers in animal and human models.
A 2022 placebo-controlled crossover trial published in Nutrients (DOI: 10.3390/nu14122377) used RNA sequencing to assess host gene expression changes following SDG supplementation. The study found that 1,450 differentially expressed genes were identified in participants who were low enterolactone excreters — demonstrating that SDG supplementation has measurable effects on gene expression pathways involved in inflammation and cellular protection, particularly in individuals with lower baseline lignan metabolism.
This finding has practical implications for supplement formulators: individual response to SDG varies based on gut microbiome composition, which may explain why some clinical trials show variable results. Combining SDG with probiotic ingredients that support enterolignan conversion (such as Lactobacillus and Bifidobacterium strains) is an emerging formulation strategy.
Regulatory and Claims Considerations by Market
For manufacturers targeting different regions, the regulatory landscape for flaxseed extract SDG claims varies:
In the European Union, flaxseed lignans can support structure/function claims related to normal hormonal activity and antioxidant protection, but medicinal claims related to menopause treatment require regulatory authorization. Formulators should work with a regulatory affairs specialist to align claims with EFSA guidance.
In the Middle East and GCC markets, women’s health supplements containing phytoestrogens are generally well-accepted, and flaxseed extract is viewed favorably as a natural, halal-compliant alternative to synthetic hormone-related ingredients. Halal certification of the extract is essential for this market.
In Southeast Asia, particularly in markets such as Malaysia, Indonesia, and Thailand, demand for natural menopause support products is growing rapidly, and flaxseed extract is increasingly included in women’s wellness formulations targeting the 40+ demographic.
Sourcing Flaxseed Extract SDG: What Manufacturers Should Specify
When sourcing flaxseed extract for supplement manufacturing, the following specifications are critical:
SDG content and test method. Specify SDG content as a percentage (typically 20%–50% for concentrated extracts) and require HPLC verification on every batch COA. Avoid suppliers who cannot provide method-specific active content data.
Non-GMO status. Flaxseed is not a GMO crop by nature, but cross-contamination during processing is possible. Non-GMO documentation protects your product labeling claims, particularly for EU and North American markets.
Heavy metal testing. As a seed-derived extract, flaxseed extract should be tested for lead, arsenic, cadmium, and mercury. Require these results on the COA.
Allergen documentation. Flaxseed is classified as an allergen in some markets. Ensure your supplier provides allergen cross-contamination data relevant to your target market regulations.
Stability data. SDG in flaxseed extract has been shown to remain stable over several months, even after heat treatment — but request stability data at your intended storage conditions to support shelf life claims on your finished product.
Flaxseed Extract SDG from Nutrayours
Nutrayours supplies high-purity Flaxseed Extract standardized for SDG content to nutraceutical manufacturers, supplement brands, and private label companies across Europe, the Middle East, and Southeast Asia.
Our flaxseed extract is manufactured under ISO 9001 certified quality management systems and carries Halal certification — making it suitable for formulations targeting Muslim-majority markets in the Middle East and Southeast Asia.
Why manufacturers choose Nutrayours for flaxseed extract:
- Standardized SDG content, HPLC verified on every batch
- Full COA including heavy metals, microbiological counts, and moisture
- Non-GMO, natural origin
- ISO 9001 and Halal certified manufacturing
- Free samples: 0.5kg–1kg available before bulk commitment
- Sample delivery: 3 days. Bulk orders: within 7 days
- Minimum bulk order: 25kg
- Factory-direct pricing — Europe, Middle East, Southeast Asia
Request a Free Sample
If you are developing a women’s health supplement, menopause support formula, or cardiovascular health product and would like to evaluate our flaxseed extract SDG, contact our team today. We provide samples with full technical documentation, including COA, specification sheet, and safety data sheet.
